| Title: | Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination |
|---|
| Authors: | ID Janžič, Urška, Klinika Golnik, Medicinska fakulteta UL (Author)
ID Bidovec, Urška, Klinika Golnik (Author)
ID Mohorčič, Katja, Klinika Golnik (Author)
ID Mrak, Loredana, Klinika Golnik (Author)
ID Fokter Dovnik, Nina (Author)
ID Ivanović, Marija (Author)
ID Ravnik, Maja (Author)
ID Čakš, Marina (Author)
ID Škof, Erik (Author)
ID Debeljak, Jerneja, Klinika Golnik (Author)
ID Korošec, Peter, Klinika Golnik, Fakulteta za farmacijo UL (Author)
ID Rijavec, Matija, Klinika Golnik, Biotehniška fakulteta UL (Author) |
|---|
| Files: |  PDF - Presentation file, download (2,03 MB)
MD5: CA4038977033DC2EEB666EA80845FD83
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
|
|---|
| Abstract: | Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, after the first and second doses and 3 months after a complete primary course of vaccination. Results were compared with healthy controls. Results: Of 112 patients, the seroconversion rate was 96%. A significant reduction in antibody levels was observed 3 months after vaccination in patients receiving immune checkpoint inhibitors versus control participants (p < 0.001). Adverse events were mostly mild. Conclusion: Immunogenicity after mRNA-based vaccine in cancer patients is adequate but influenced by the type of anticancer therapy. Antibody levels decline after 3 months, and thus a third vaccination is warranted. |
|---|
| Keywords: | onkološko zdravljenje, imunogenost, osnovno cepljenje mRNA, čvrsti tumorji, anticancer treatment, immunogenicity, mRNA-based vaccination, solid cancer |
|---|
| Publication status: | In print |
|---|
| Publication version: | Author Accepted Manuscript |
|---|
| Place of publishing: | Velika Britanija |
|---|
| Publisher: | Future Medicine |
|---|
| Year of publishing: | 2022 |
|---|
| Number of pages: | str. [1-10] |
|---|
| Numbering: | Vol. , iss. |
|---|
| PID: | 20.500.12556/DiRROS-15227  |
|---|
| UDC: | 616-006 |
|---|
| ISSN on article: | 1479-6694 |
|---|
| DOI: | 10.2217/fon-2022-0148 |
|---|
| COBISS.SI-ID: | 111378179 |
|---|
| Copyright: | (C) 2022 The Authors |
|---|
| Note: | Soavtorji: Urška Bidovec-Stojković, Katja Mohorčič, Loredana Mrak, Nina Fokter Dovnik, Marija Ivanović, Maja Ravnik, Marina Čaks, Erik Škof, Jerneja Debeljak, Peter Korošec & Matija Rijavec;
|
|---|
| Publication date in DiRROS: | 24.06.2022 |
|---|
| Views: | 1201 |
|---|
| Downloads: | 500 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
